SEC Tracker
Get the app

Organicell Regenerative Medicine ZEOX

Organicell Regenerative Medicine FY 2023: revenue $4.6M, down 30%; diluted EPS −$0.99

Form
10-K
Filed
Period
Importance
Notable
Document
10-K

Key figures from this report

These are the numbers Organicell Regenerative Medicine reported for the year ended Oct 31, 2023, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$4.6M−30% from $6.5M in FY 202210-K income statement, on EDGAR
  2. Net income−$7.0MAgainst −$8.9M in FY 202210-K income statement, on EDGAR
  3. Diluted EPS−$0.99Against −$1.56 in FY 202210-K income statement, on EDGAR
  4. Cash and cash equivalents$1.8M−53% from $3.8M in FY 202210-K balance sheet, on EDGAR
  5. Cash from operations−$2.2MAgainst −$3.2M in FY 202210-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Organicell Regenerative Medicine files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Sunshine Biopharma SBFM public float $7M, Jun 30, 2025
  2. Neuphoria Therapeutics NEUP public float $7M, Dec 31, 2025
  3. CV Sciences CVSI public float $7M, Jun 30, 2025
  4. Minerva Neurosciences NERV public float $7M, Jun 30, 2025
  5. Bolt Biotherapeutics BOLT public float $7M, Jun 30, 2025